Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Clinical trial NCT05218603 · UNKNOWN

Trial details

NCT number: NCT05218603
Sponsor: PETHEMA Foundation
Status: UNKNOWN
Study type: OBSERVATIONAL

Multiple Myeloma Non-eligible for Autologous Stem Cell Transplantation (ASCT)

Start date: 2021-11-30
Primary completion: 2025-11-06
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.